Physician profile
Scott Daniel Seifert
NPI 1124510268
$5,946.44
in general payments reported to CMS, 2019-2025
32 companies · $2,013 in 2025
The $2,013 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $368 · 2023: $1,994 · 2024: $1,572 · 2025: $2,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,578.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,106.49 | 2022-2025 | Linzess, Viberzi, Vraylar |
| Glaxosmithkline, LLC. | $841.28 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $741.21 | 2023-2025 | |
| Novo Nordisk INC | $678.67 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $470.26 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Steris Corporation | $157.66 | 2023 | |
| Lilly USA, LLC | $156.50 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $149.06 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $136.22 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.17 | 2022-2025 | Jardiance, Stiolto Respimat |
| Edwards Lifesciences Corporation | $118.88 | 2023-2024 | |
| Exact Sciences Corporation | $115.46 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $112.60 | 2023-2025 | Veozah, Myrbetriq |
| Xeris Pharmaceuticals, INC. | $109.32 | 2024-2025 | Keveyis |
| Phathom Pharmaceuticals, INC. | $106.95 | 2024-2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $103.02 | 2024-2025 | Nexletol |
| Amgen INC. | $94.03 | 2022-2024 | Evenity, Prolia, Repatha |
| E.R. Squibb & Sons, L.L.C. | $76.07 | 2022-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $74.09 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $73.29 | 2023 | |
| Daiichi Sankyo INC. | $70.90 | 2022-2023 | Injectafer |
| Sanofi Pasteur INC. | $61.94 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $50.75 | 2024-2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.04 | 2023-2024 | Xifaxan, Trulance |
| Csl Behring | $39.33 | 2025 | Haegarda, Andembry |
| Dexcom, INC. | $31.52 | 2024-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.63 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $17.29 | 2022 | |
| Sumitomo Pharma America, INC. | $16.55 | 2024 | Gemtesa |
| Cipher Pharmaceuticals US LLC | $16.36 | 2025 | Natroba, Spinosad |
| Nestle Healthcare Nutrition INC. | $15.48 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.42 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Seifert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.